iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. lessened its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 13.7% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 95,240 shares of the company’s stock after selling 15,149 shares during the period. Victory Capital Management Inc.’s holdings in iTeos Therapeutics were worth $972,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Candriam S.C.A. purchased a new stake in iTeos Therapeutics in the 2nd quarter valued at approximately $7,558,000. Clearline Capital LP purchased a new stake in iTeos Therapeutics in the 2nd quarter valued at approximately $2,328,000. Kennedy Capital Management LLC purchased a new stake in iTeos Therapeutics in the 1st quarter valued at approximately $1,988,000. Dimensional Fund Advisors LP boosted its holdings in iTeos Therapeutics by 14.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock valued at $13,481,000 after purchasing an additional 117,159 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in iTeos Therapeutics in the 3rd quarter valued at approximately $263,000. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Price Performance

Shares of NASDAQ:ITOS opened at $8.54 on Thursday. The business’s 50 day simple moving average is $9.23 and its 200-day simple moving average is $13.74. The firm has a market capitalization of $312.00 million, a price-to-earnings ratio of -2.71 and a beta of 1.39. iTeos Therapeutics, Inc. has a 12 month low of $7.54 and a 12 month high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last posted its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.13. On average, equities analysts anticipate that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. lowered their price objective on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. Wells Fargo & Company began coverage on iTeos Therapeutics in a research note on Tuesday, August 13th. They set an “overweight” rating and a $31.00 price target on the stock. Wedbush reissued an “outperform” rating and set a $25.00 price target on shares of iTeos Therapeutics in a research note on Tuesday, November 12th. Finally, HC Wainwright reissued a “buy” rating and set a $46.00 price target on shares of iTeos Therapeutics in a research note on Friday, November 15th.

Insider Activity at iTeos Therapeutics

In related news, CFO Matthew Gall bought 5,000 shares of iTeos Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The shares were purchased at an average price of $7.73 per share, with a total value of $38,650.00. Following the purchase, the chief financial officer now owns 65,429 shares in the company, valued at $505,766.17. This represents a 8.27 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 12.50% of the stock is owned by corporate insiders.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.